Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00463021 · ClinicalTrials.gov registry record · Phase 4
A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection
A Phase 4 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT00463021: Completed Phase 4 study, sponsored by Genzyme, a Sanofi Company.
NCT00463021 is a Phase 4 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 36 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00463021, a Phase 4 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic kidney disease on hemodialysis.
Interventions
- DRUG Hectorol (doxercalciferol capsules)
- DRUG Zemplar (paricalcitol injection)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
What the finished NCT00463021 record still lists
NCT00463021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Hectorol (doxercalciferol capsules) is the first listed.
NCT00463021 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00463021 about?
NCT00463021 is a clinical study titled "A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection". Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic kidney disease on hemodialysis.
What is the current status of trial NCT00463021?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2007-04. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00463021?
The interventions under investigation include: Hectorol (doxercalciferol capsules) (DRUG), Zemplar (paricalcitol injection) (DRUG).
Who is sponsoring clinical trial NCT00463021?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00463021's enrollment target sits among peer trials
36 1490th of 2000 higher than 495 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia